High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease

Serena Bugatti, Antonio Manzo, Barbara Vitolo, Francesca Benaglio, Elisa Binda, Martina Scarabelli, Frances Humby, Roberto Caporali, Costantino Pitzalis, Carlomaurizio Montecucco

Research output: Contribution to journalArticlepeer-review

Abstract

Objective. The B cell chemoattractant chemokine ligand 13 (CXCL13) is emerging as a new biochemical marker in RA. This study was undertaken to dissect the relationship between CXCL13 expression levels in the synovium and clinico-pathological variables relevant to RA pathogenesis and outcome. Methods. Synovial tissues from 71 RA patients were evaluated by immunohistochemistry. Thirty paired samples were used for comparative gene expression analysis by quantitative real-time PCR. CXCL13 levels were analysed in relation to cellular, molecular and clinical features of inflammation, lymphocyte activation and joint damage. Results. In patients with early disease (

Original languageEnglish
Pages (from-to)1886-1895
Number of pages10
JournalRheumatology
Volume53
Issue number10
DOIs
Publication statusPublished - Oct 1 2014

Keywords

  • B lymphocytes
  • Biomarkers
  • CXCL13
  • Rheumatoid arthritis
  • Synovium

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease'. Together they form a unique fingerprint.

Cite this